Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease

Movement Disorders : Official Journal of the Movement Disorder Society
N SyedJ I Sage

Abstract

We report our long-term experience using enteral levodopa infusions in 22 patients with Parkinson's disease and severe motor fluctuations. Amelioration of intractable dyskinesias was the most important factor that determined whether patients chose to continue using the infusion pump system. Mechanical and physical problems associated with enteral access were the most common reasons for which patients discontinued pump use. Nearly all patients continued to have dramatically increased on time for the duration of follow up, suggesting that technically less-cumbersome systems that provide continuous dopaminergic stimulation are worthwhile and should be developed.

References

Apr 1, 1989·Neurology·J R Keane
Jul 1, 1988·Annals of Neurology·J I SageR C Duvoisin
Apr 1, 1995·Neurology·M DogaliA Berić

❮ Previous
Next ❯

Citations

Sep 29, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·E LugingerW Poewe
Aug 14, 2003·Parkinsonism & Related Disorders·Fabrizio Stocchi
Oct 29, 2000·Trends in Neurosciences·J G NuttF Stocchi
Aug 26, 2006·Nature Clinical Practice. Neurology·C Warren OlanowFabrizio Stocchi
Oct 6, 2000·Clinical Neuropharmacology·A Hadj TaharP J Bédard
Jun 5, 2003·Clinical Neuropharmacology·Dag NyholmSten-Magnus Aquilonius
Dec 17, 2004·Clinical Neuropharmacology·Dag Nyholm, Sten-Magnus Aquilonius
Dec 14, 2011·The Neurologist·Maria Cruz Rodriguez-OrozOriol de Fabregues
Sep 3, 2009·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A H SchapiraE Tolosa
Sep 21, 2010·Clinical Interventions in Aging·Werner PoeweFrançois Vingerhoets
Jul 11, 2006·Drugs & Aging·Lorenzo PrianoAlessandro Mauro
Jul 13, 2013·Journal of Neurology, Neurosurgery, and Psychiatry·Aristide MerolaLeonardo Lopiano
Mar 23, 2007·Expert Opinion on Pharmacotherapy·Johan Samanta, Robert A Hauser
Mar 13, 2014·Expert Opinion on Drug Safety·Wolfgang H Jost
Apr 23, 2009·Expert Opinion on Drug Delivery·Antonio Di StefanoLaura Serafina Cerasa
Jun 30, 2006·Expert Opinion on Pharmacotherapy·Fabrizio Stocchi
Aug 22, 2015·Journal of Neural Transmission·Heinz Reichmann
May 6, 2015·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Giovanni CossuAngelo Antonini
Feb 19, 2010·Expert Opinion on Pharmacotherapy·Gianni Pezzoli, Michela Zini
Apr 15, 2016·Neurodegenerative Disease Management·Diego Santos GarcíaNatividad Mariscal Pérez
Mar 1, 2009·Therapeutic Advances in Neurological Disorders·O K Sujith, Carol Lane
Sep 17, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·C Warren OlanowFabrizio Stocchi
Oct 19, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Lance A SmithPeter Jenner
Sep 8, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·John G Nutt
Sep 11, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·C Warren Olanow
Sep 11, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Fabrizio StocchiC Warren Olanow
Feb 27, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Tomas Bjorklund, Jeffrey H Kordower
Dec 19, 2003·Acta Veterinaria Hungarica·G SzucsIrén Mikó
Jun 1, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Olivier RascolWerner Poewe
Apr 7, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Aristide MerolaLeonardo Lopiano
Mar 21, 2002·Acta Neurologica Scandinavica·D NilssonS M Aquilonius
Oct 18, 2005·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Anthony E LangOksana Suchowersky
Mar 27, 2004·Current Treatment Options in Neurology·Jacob I. Sage
Oct 12, 2018·Issues in Mental Health Nursing·Marian W Roman
Aug 8, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Stephen D Aradi, Robert A Hauser

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.